Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Breast Neoplasms 8Neoplasms 7Lung Neoplasms 7Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Melanoma 3Skin Neoplasms 2Neoplastic Cells, Circulating 2Lung Diseases 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Brain Neoplasms 2von Hippel-Lindau Disease 1Weight Loss 1Uterine Cervical Neoplasms 1Sleep Apnea Syndromes 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Ovarian Insufficiency 1Pituitary Neoplasms 1Pancreatic Neoplasms 1Overweight 1Obesity, Morbid 1Obesity 1Nervous System Diseases 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1

Interventions

entinostat 1Pharmacogenomic Testing 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Anatomic Stage III Breast Cancer AJCC v8 × Blood Specimen Collection × Clear all
NCT02453620 2026-04-13

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
57 enrolled
BreastOther solid neoplasm

Anatomic Stage III Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡